Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 89

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 89
---
, a research-based organization focused on autologous dendritic cell-based tumor vaccines. Prior to joining Medac GmbH, Dr.
Kosciessa was a postdoctoral researcher at the neuroscience/neurodegenerative diseases division of Schering AG, a multinational pharmaceutical
company. He received a B. Sc. in Biology and a Ph. D. in Molecular Biology from Georg-August University of Göttingen, Germany.

Pierre Labbéserves as a director on
our board. Mr. Labbé has more than 30 years of progressive financial leadership roles in various industries. Mr. Labbé
is currently the Executive Vice-President, Finance of Fonds QScale S. E. C., which is actively developing environmentally responsible computing
centers, where he oversees financial strategy, investor relations, financial reporting, tax, treasury and risk management. Prior to joining
Fonds QScale S. E. C., Mr. Labbé was the Chief Financial Officer of IMV Inc. for five years. Among other positions, he also previously
served as Chief Financial Officer and Corporate Secretary of LeddarTech Inc. and Medicago Inc. (TSX). In addition, Mr. Labbé has
been a director of Osisko Gold Royalties Ltd. a TSX- and NYSE-listed precious metal royalty company, since 2015, and currently serves
as the Chair of its Human Resources Committee and as a member of its Audit and Risk Committee. As Senior Financial Officer, Pierre has
played a key role in financing and mergers and acquisitions, overseeing transactions exceeding $1 billion. Mr. Labbé holds
a Bachelor’s Degree in Business Administration and a license in accounting from Université Laval, Québec City. He
is a member of the Chartered Professional Accountants of Canada, Quebec Chartered Professional Accountants Order and the Institute of
Corporate Directors. He also holds the ICD. D designation from the Institute of Corporate Directors.

Giuliano La Frattawas appointed as our Senior
Vice President, Chief Financial Officer in January 2022. He is a senior financial professional with over 20 years of professional experience
in the pharmaceutical, biopharma and financial services sector. During his career, he has served in both the public and private sectors
where he has gained significant experience in leading and managing broad financial activities, including M& A transactions, corporate
development, auditing, accounting and administrative functions. Prior to joining Aeterna Zentaris, Mr. La Fr